Q1 Earnings Estimate for Xencor Issued By William Blair

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Stock analysts at William Blair issued their Q1 2025 earnings estimates for Xencor in a research report issued on Monday, April 21st. William Blair analyst M. Phipps forecasts that the biopharmaceutical company will post earnings of ($0.84) per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Xencor's current full-year earnings is ($3.68) per share. William Blair also issued estimates for Xencor's Q2 2025 earnings at ($0.82) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($3.27) EPS, FY2026 earnings at ($3.15) EPS, FY2027 earnings at ($3.01) EPS and FY2028 earnings at ($3.05) EPS.

A number of other research analysts have also issued reports on the company. StockNews.com lowered Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Wells Fargo & Company reduced their target price on Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Xencor currently has a consensus rating of "Moderate Buy" and an average target price of $33.86.

Xencor Trading Up 0.5 %

NASDAQ:XNCR traded up $0.05 during trading hours on Wednesday, reaching $10.56. 93,318 shares of the stock were exchanged, compared to its average volume of 626,600. The company has a market capitalization of $751.29 million, a price-to-earnings ratio of -3.30 and a beta of 0.90. Xencor has a twelve month low of $7.16 and a twelve month high of $27.24. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average of $11.77 and a two-hundred day moving average of $18.41.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC grew its holdings in Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 508 shares during the period. KBC Group NV grew its stake in shares of Xencor by 26.0% during the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock valued at $90,000 after buying an additional 813 shares during the period. Sterling Capital Management LLC raised its position in shares of Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 1,040 shares during the period. New York State Teachers Retirement System boosted its holdings in Xencor by 2.1% in the first quarter. New York State Teachers Retirement System now owns 59,326 shares of the biopharmaceutical company's stock valued at $631,000 after acquiring an additional 1,200 shares during the last quarter. Finally, Summit Investment Advisors Inc. grew its position in Xencor by 22.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company's stock valued at $162,000 after acquiring an additional 1,282 shares during the period.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.